The study assesses the extent to which member countries of the African Regional Intellectual Property Organization (ARIPO) have taken advantage of flexibility in the global trade restrictions in TRIPS to provide medicine for their infected citizens. It draws on interviews with policy makers, manufacturers, and national drug regulatory authorities in Ghana, Kenya, Mozambique, South Africa, and Zimbabwe.